Corbus Pharmaceuticals Holdings, Inc.

NASDAQ:CRBP

Biotechnology

Healthcare
$2.75 +1.73%

+$0.14 today

Market cap
$56.57M
Beta
2.59
P/E (TTM)
-1.3
EPS (TTM)
-$6.35
52W Low $6.72High $20.56

Volume 0.63M

Average 0.42M

CRBP Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Corbus Pharmaceuticals Holdings, Inc.NASDAQ: CRBP

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin not reported for Q1 FY2026

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
—— QoQ
Last fiscal yearDec 2025
—— YoY
LTMMar 2026
—— YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2021
-85.9%
Year-over-year change
—

Gross Margin vs competitors

How CRBP compares with its peers on the latest reported figures

CRBP Competitors Peer median
Gross Margin for CRBP and competitors
Company Period LTM level YoY 3-year change
IPHAInnate Pharma S.A.FY2025100.0% +0.0 pp+89.6 pp
RANIRani Therapeutics Holdings, Inc.LTM Mar 202694.9% -5.1 pp—
MISTMilestone Pharmaceuticals Inc.LTM Mar 202694.7% —-7.4 pp
ALECAlector, Inc.LTM Mar 2026-61.2% -68.0 pp-45.9 pp
CRDFCardiff Oncology, Inc.LTM Mar 2026-2105.7% -548.4 pp+0.0 pp
CRBPCorbus Pharmaceuticals Holdings, Inc.FY2025— ——
FBRXForte Biosciences, Inc.FY2025— ——
PEPGPepGen Inc.FY2025— ——
MOLNMolecular Partners AGFY2025— ——
ELTXElicio Therapeutics, Inc.FY2025— ——
Peer median (excluding CRBP) 94.7%-36.5 pp-3.7 pp

Competitors are the stored peer set for CRBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue881.71K0000
Cost of Revenue1.64M1.49M0600K0
Gross Profit(757.53K)(1.49M)0(600K)0
Gross Margin-85.9%————
Research & Development36.45M16.14M31.17M32.22M70.1M
Selling, General & Admin20.43M18.7M13.91M16.5M15.22M
Operating Expenses55.23M33.35M45.08M48.12M85.31M
Depreciation & Amortization1.64M1.49M641K600K233K
EBITDA(42.17M)(38.73M)(40.11M)(37.74M)(78.3M)
EBITDA Margin-4782.9%————
Operating Income(55.99M)(34.84M)(45.08M)(48.72M)(85.31M)
Operating Margin-6350.1%————
Interest Income0006.31M5.53M
Interest Expense1.83M2.13M2.92M1.87M0
Other Income / Expenses10.35M(7.51M)474K8.51M6.77M
Income Before Tax(45.64M)(42.35M)(44.6M)(40.21M)(78.54M)
Pre-Tax Margin-5176.4%————
Income Tax Expense00000
Net Income(45.55M)(55.83M)(44.6M)(40.21M)(78.54M)
Net Margin-5166.4%————
EPS (Basic)(11.13)(10.15)(10.31)(3.68)(5.90)
EPS (Diluted)(11.13)(10.15)(10.31)(3.68)(5.90)
Weighted Avg Shares4.1M4.17M4.33M10.92M13.32M
Weighted Avg Shares (Diluted)4.1M4.17M4.33M10.92M13.32M

Corbus Pharmaceuticals Holdings, Inc.

NASDAQ:CRBP

Intrinsic Alpha fair value

Locked

Current Price

$2.75

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.